Snelix, an Italian biotech startup focused on extracting bio-active peptides from snail mucus, has secured over €1 million through three separate public grant programmes to accelerate its research and development efforts in the cosmeceutical and nutraceutical sectors.
The funding was obtained through the Smart & Start, Tecnonidi, and Pre-seed grant schemes, representing a strategic approach to capital raising that allows the company to advance its technology while minimizing equity dilution. The combination of public funding with complementary private investor backing provides Snelix with the resources needed to scale its operations during this critical pre-seed stage.
Advancing Peptide Extraction Technology
The company plans to deploy the funds across three primary areas: developing its peptide extraction technology, formulating consumer-ready cosmeceutical and nutraceutical products, and building out production capacity. This multifaceted approach reflects Snelix’s ambition to move beyond laboratory research into commercialization.
Snail mucus has emerged as a compelling natural source for bioactive compounds in recent years, with the slime containing proteins and peptides that possess potential anti-inflammatory, moisturizing, and regenerative properties. By isolating and processing these peptides, Snelix aims to create proprietary ingredients for both topical beauty applications and oral health and wellness products.
Supporting European Biotech Innovation
The successful acquisition of these Italian public grants underscores the importance of government-backed funding mechanisms in supporting early-stage biotech ventures. Smart & Start, Tecnonidi, and Pre-seed are Italian initiatives designed to nurture innovation-driven startups, particularly those developing novel technologies with commercial potential.
For Snelix, this funding strategy demonstrates how emerging European biotech companies can leverage public resources to de-risk product development and reach commercial milestones. The pre-seed stage represents a critical juncture where companies validate core technology and business models before pursuing larger rounds of venture capital.
The broader European startup ecosystem continues to generate interest in biotech innovation, particularly in sectors like healthtech and cosmeceuticals where consumer demand for natural, science-backed ingredients remains strong. Italy’s startup landscape has increasingly attracted attention for its support of deep-tech and biotech ventures, with government programmes playing a vital role in enabling companies to compete internationally.
Snelix’s funding success reflects growing recognition that sustainable, nature-inspired solutions to beauty and wellness challenges represent a viable business opportunity. As the company progresses through product development and market validation, its trajectory will likely offer insights into how Italian biotech startups can scale within a competitive European market. The combination of public grants and private investment positions the startup to establish itself as a notable player in the emerging peptide-based cosmeceuticals space.